recent
emphasi
fund
train
opportun
global
health
humanitarian
aid
increas
interest
field
mani
health
care
worker
medic
research
travel
resourcereplet
resourcelimit
set
type
travel
bring
uniqu
diseas
risk
routin
consid
busi
vacat
travel
review
provid
practic
advic
special
popul
travel
target
specif
health
carerel
risk
needlestick
hemorrhag
fever
virus
sever
viral
respiratori
diseas
tuberculosi
suggest
risk
mitig
data
epidemiolog
infecti
diseas
occur
among
travel
health
care
worker
hcw
exist
surveil
system
classifi
group
separ
busi
vacat
travel
record
instead
tourist
missionari
other
furthermor
hcw
divers
group
rang
shortterm
travel
worker
refuge
camp
consequ
individu
activ
travel
destin
around
globe
pose
vari
risk
import
consid
intersect
host
agent
vector
environ
hcw
occup
travel
region
high
diseas
endem
compound
risk
work
specif
microenviron
health
care
set
high
concentr
potenti
infecti
human
vector
patient
staff
environ
often
offer
protect
present
develop
world
engin
control
person
protect
equip
ppe
place
travel
hcw
greater
risk
infect
factor
need
address
determin
risk
prepar
mitig
plan
travel
provid
prophylaxi
vaccin
bring
ppe
medic
countermeasur
anti
retrovir
antibiot
hand
must
consid
tabl
pretravel
advic
manag
needlestick
injuri
start
discuss
prevent
needlestick
may
like
occur
crowd
rush
unfamiliar
work
set
advis
hcw
set
sharp
contain
one
avail
potenti
substitut
includ
empti
contain
soda
plastic
laundri
deterg
bottl
awar
diseas
epidemiolog
region
among
potenti
patient
help
risk
assess
needlestick
injuri
occur
addit
human
immunodefici
viru
hiv
hepat
virus
virus
transmit
needlestick
dengu
viru
hemorrhag
fever
virus
potenti
diseas
risk
includ
syphili
mycobacteri
rickettsi
infect
trypanosomiasi
viscer
leishmaniasi
malaria
malaria
particularli
notabl
risk
diseas
needlestick
may
higher
hepat
virus
hiv
fatal
nearfat
case
occur
result
diagnost
delay
know
preval
drug
resist
needlesticktransmiss
endem
diseas
also
use
needlestick
injuri
occur
hcw
note
sourc
patient
region
origin
present
complaint
histori
physic
find
perform
rapid
hiv
test
obtain
blood
sampl
later
test
wash
injuri
site
thoroughli
warm
water
soap
caustic
antisept
eg
bleach
povidon
iodid
recommend
may
ac
tualli
increas
risk
infect
result
local
tissu
injuri
recruit
inflammatori
cell
clear
plan
followup
assess
point
contact
essenti
given
diagnost
test
hepat
virus
hiv
may
limit
oversea
destin
hcw
consid
complet
baselin
test
travel
hepat
b
viru
hbv
one
transmiss
virus
relat
needlestick
gener
common
resourcelimit
set
unit
state
risk
unvaccin
person
sourc
posit
hepat
b
e
antigen
hbeag
sourc
neg
hbeag
posit
hepat
b
surfac
antigen
hbsag
transmiss
environment
surfac
occur
even
without
cutan
injuri
fortun
hbv
vaccin
highli
effect
elimin
risk
respond
primari
seri
respond
repeat
vaccin
may
protect
repeat
seri
check
antibodi
hepat
b
core
antigen
hbsag
ensur
patient
chronic
hbv
carrier
deep
intramuscular
inject
longer
needl
may
need
larger
recipi
serostatu
neg
immun
benefit
addit
vaccin
seroneg
hcw
remain
high
risk
hepat
b
expos
hepat
b
immunoglobulin
mlkg
intramuscularli
offer
injuri
repeat
month
hepat
b
immunoglobulin
start
within
week
exposur
provid
protect
tenofovir
lamivudin
activ
hbv
guidanc
prophylact
use
set
consid
administr
hepat
b
immunoglobulin
departur
seroneg
hcw
concern
exist
hbv
exposur
remot
set
passiv
antibodi
halflif
week
level
measur
month
although
prophylaxi
hepat
c
viru
hcv
exposur
exist
needlestick
transmiss
risk
lower
transmit
infect
resolv
spontan
incub
period
week
expos
individu
monitor
hcv
rna
test
avail
immedi
treatment
recommend
light
signific
toxic
durat
therapi
infect
resolv
spontan
treatment
consid
hcv
infect
remain
establish
week
fear
hiv
infect
needlestick
lowest
risk
transmiss
time
initi
postexposur
prophylaxi
pep
critic
pep
effect
start
immedi
definit
start
within
day
exposur
pep
must
continu
week
unlik
hiv
treatment
use
tripledrug
combin
essenti
success
factor
drug
unlik
significantli
better
pep
paradox
may
less
effect
given
adher
regimen
poorer
toxic
multidrug
regimen
zidovudin
monotherapi
effect
prevent
infect
world
health
organ
recommend
use
nucleosid
reversetranscriptas
inhibitor
countri
firstlin
regimen
drug
sourc
patient
known
infect
drugresist
hiv
resist
commun
center
diseas
control
prevent
cdc
recommend
pep
regimen
sourc
patient
known
infect
hiv
sourc
devic
hollowbor
needl
visibl
blood
contamin
cdc
recommend
zidovudin
stavudin
tenofovir
plu
emtricitabin
lamivudin
third
drug
includ
cdc
recommend
ritonavirboost
proteas
inhibitor
nonnucleosid
reversetranscriptas
inhibitor
hcw
strongli
encourag
bring
postexposur
medic
destin
follow
needlestick
injuri
includ
high
level
suspicion
febril
ill
week
incid
serolog
test
hiv
hepat
syphili
month
adher
support
antiretrovir
given
hiv
rna
check
acut
febril
ill
hivposit
needlestick
exposur
hcv
rna
measur
avail
monitor
week
highrisk
exposur
viral
hemorrhag
fever
vhf
acut
febril
syndrom
accompani
bleed
diathesi
caus
famili
singlestrand
rna
virus
filovirus
arenavirus
bunyavirus
flavivirus
nosocomi
spread
infect
hcw
potenti
risk
mitig
earli
recognit
appropri
precaut
first
step
protect
know
virus
endem
local
area
shown
tabl
human
infect
via
bite
arthropod
vector
inhal
ingest
rodent
excret
mucos
percutan
contact
infect
blood
secret
patient
underresourc
set
spread
virus
hospit
environ
often
facilit
lack
recognit
reus
equip
contamin
needl
inconsist
enforc
basic
infectioncontrol
practic
frequent
inadequ
suppli
clinic
diagnosi
vhf
requir
index
suspicion
challeng
especi
underdevelop
region
broad
differenti
diagnosi
acut
febril
ill
includ
malaria
typhoid
rickettsi
ill
leptospirosi
common
present
symptom
includ
acut
onset
fever
malais
headach
myalgia
prostrat
frequent
accompani
gastrointestin
complaint
earli
sign
may
includ
pharyng
conjunct
cutan
flush
maculopapular
rash
hemorrhag
manifest
may
includ
ooz
intraven
punctur
site
petechia
purpura
larg
ecchymos
frank
hemorrhag
howev
manifest
frequenc
sever
bleed
vari
depend
agent
case
fatal
rate
rang
rift
valley
fever
nearli
ebola
marburg
fever
specif
diagnosi
made
basi
detect
viru
viral
antigen
serum
plasma
whole
blood
antigencaptur
antibodydetect
enzymelink
immunosorb
assay
reversetranscript
polymeras
chain
reaction
viral
isol
attempt
biosafeti
level
contain
laboratori
cdc
us
armi
medic
research
institut
infecti
diseas
hemorrhag
fever
virus
except
dengu
viru
known
infect
via
artifici
produc
aerosol
laboratori
environ
potenti
spread
laboratori
anim
rais
concern
potenti
persontoperson
airborn
transmiss
howev
epidemiolog
vhf
outbreak
indic
persontoperson
airborn
transmiss
occur
rare
zair
ebola
epidem
infect
hcw
declin
dramat
institut
isol
precaut
howev
achiev
univers
adher
strict
isol
precaut
hot
humid
condit
environ
challeng
demonstr
ebola
outbreak
uganda
specif
guidanc
infect
control
avail
standard
contact
droplet
precaut
use
privat
room
inpati
outpati
set
although
airborn
precaut
requir
earlier
stage
ill
consid
earli
elimin
need
later
transfer
airborn
isol
room
sever
pulmonari
involv
certain
activ
might
stimul
cough
gener
aerosol
eg
bronchoscopi
endotrach
intub
cdc
develop
vhf
infectioncontrol
recommend
african
health
care
set
applic
auster
environ
handbook
recommend
practic
measur
establish
standard
precaut
patient
routin
hand
wash
safe
handl
dispos
use
needl
syring
upgrad
vhf
precaut
includ
isol
patient
wear
protect
cloth
scrub
suit
gown
apron
glove
mask
headcov
eyewear
rubber
boot
hcw
train
occur
advanc
access
patient
care
area
limit
definit
need
cdc
identifi
level
risk
casual
close
highrisk
contact
potenti
exposur
along
followup
recommend
vhf
vaccin
current
licens
unit
state
yellow
fever
investig
vaccin
exist
sever
vhf
howev
undergo
anim
clinic
test
laboratori
worker
gener
avail
medic
countermeasur
limit
postexposur
situat
expert
consult
treatment
prophylaxi
measur
recommend
recent
emerg
sever
respiratori
viral
diseas
prompt
intensifi
research
public
health
concern
coronaviru
caus
sever
acut
respiratori
syndrom
sarscov
spread
rapidli
result
pandem
frequent
nosocomi
spread
reemerg
human
popul
avian
influenza
rais
intern
alarm
potenti
novel
influenza
pandem
widespread
infect
poultri
wild
bird
continu
caus
occasion
human
case
southeast
asia
middl
east
although
humantohuman
transmiss
limit
case
fatal
rate
exce
recent
influenza
reassort
zoonot
influenza
viru
emerg
north
america
spread
throughout
world
result
pandem
declar
june
april
confirm
case
produc
least
death
report
countri
pandem
viru
effect
replac
previous
circul
season
influenza
strain
research
hcw
face
obviou
risk
occup
acquisit
respiratori
diseas
limit
data
quantifi
actual
risk
exist
although
compel
anecdot
document
potenti
danger
protect
measur
mitig
risk
exposur
includ
contact
respiratori
precaut
optim
strategi
depend
natur
pathogen
known
suspect
transmiss
rout
exposur
circumst
transmiss
sarscov
appear
occur
predominantli
close
interact
infect
person
pandem
transmiss
hcw
occur
close
unprotect
contact
symptomat
person
significantli
mitig
infectioncontrol
precaut
implement
degre
risk
relat
type
intens
exposur
endotrach
intub
significantli
associ
contract
sar
airborn
transmiss
sarscov
clearli
suggest
model
studi
retrospect
evalu
nosocomi
outbreak
anecdot
report
transmiss
aboard
commerci
aircraft
transmiss
human
influenza
virus
occur
via
larg
droplet
direct
indirect
contact
droplet
nuclei
rel
contribut
rout
known
like
vari
set
circumst
conflict
opinion
regard
import
airborn
transmiss
influenza
virus
human
direct
contact
may
import
inhal
condit
high
humid
temperatur
frequent
dilig
hand
hygien
like
import
intervent
interrupt
transmiss
mani
respiratori
virus
particularli
influenza
viru
clean
water
avail
field
set
alcoholbas
hand
gel
use
gel
andor
wash
soap
water
demonstr
effect
personnel
train
use
protect
cloth
glove
shoe
cover
goggl
mask
princip
question
respect
respiratori
protect
whether
mask
fit
higheffici
particlefilt
respir
answer
depend
rel
contribut
aerosol
versu
larg
droplet
diseas
transmiss
cite
evid
observ
studi
hospit
suggest
droplet
transmiss
respons
major
nosocomi
acquir
case
recommend
standard
plu
droplet
precaut
person
season
influenza
recent
result
suggest
surgic
mask
effect
prevent
season
influenza
although
controversi
exist
pandem
institut
medicin
panel
recommend
hcw
use
mask
given
uncertainti
regard
risk
transmiss
resourcelimit
set
prioriti
given
riskreduct
intervent
focus
hand
hygien
contact
precaut
expedi
respiratori
protect
use
ppe
effect
aerosol
respiratori
protect
particularli
exposur
like
gener
aerosol
eg
intub
although
heterotyp
protect
novel
strain
pathogen
expect
influenza
vaccin
recommend
individu
involv
respiratori
diseas
research
hcw
care
patient
unless
contraind
vaccin
recommend
decreas
risk
ill
due
season
influenza
viru
reduc
frequenc
diagnost
manag
dilemma
occup
involv
close
contact
individu
sever
respiratori
diseas
caus
influenza
sar
prevent
influenza
mean
chemoprophylaxi
neuraminidas
inhibitor
potenti
strategi
may
indic
certain
set
direct
contact
sourc
avian
influenza
gener
tuberculosi
potenti
threat
hcw
research
travel
work
highburden
countri
approxim
new
case
multidrugresist
mdr
tuberculosi
defin
tuberculosi
resist
isoniazid
rifampin
report
treat
accord
standard
extens
drugresist
xdr
tuberculosi
defin
mdr
tuberculosi
plu
resist
fluoroquinolon
secondlin
inject
kanamycin
amikacin
capreomycin
report
countri
mdr
xdr
tuberculosi
pose
special
risk
recognit
infecti
individu
difficult
lack
laboratori
infrastructur
cultur
suscept
test
treatment
mdr
xdr
tuberculosi
prolong
signific
toxic
poor
outcom
treatment
complet
cure
report
mdr
case
xdr
case
epidemiolog
drugresist
tuberculosi
describ
fourth
global
report
inform
incomplet
region
especi
africa
medic
literatur
identifi
seriou
problem
mdr
xdr
tuberculosi
china
repres
global
burden
india
repres
countri
former
soviet
union
highest
proport
drug
resist
case
mdr
tuberculosi
countri
high
proport
mdr
tuberculosi
rate
vietnam
thailand
korea
philippin
peru
guatemala
good
infect
control
atrisk
screen
treatment
latent
tuberculosi
nosocomi
transmiss
rare
unit
state
exposur
oversea
may
occur
locat
uncontrol
transmiss
inadequ
infectioncontrol
practic
exposur
like
hospit
also
clinic
hospic
prison
factori
mine
orphanag
offic
hcw
counsel
regard
tuberculosi
risk
departur
evalu
return
mani
unawar
risk
symptom
develop
diagnosi
often
delay
allow
potenti
transmiss
vulner
popul
us
medic
facil
departur
risk
tuberculosi
destin
assess
hcw
screen
latent
tuberculosi
interferon
g
releas
assay
igra
tuberculin
skin
test
tst
igra
specif
prefer
histori
bacil
bcg
vaccin
result
tst
igra
neg
vaccin
bcg
may
consid
month
departur
bj
person
commun
two
month
return
rescreen
igra
fit
test
either
dispos
filter
facepiec
respir
reusabl
elastomer
respir
advis
facial
hair
adequ
seal
possibl
power
air
purifi
respir
need
respiratori
protect
brought
destin
infectioncontrol
guidelin
resourcelimit
countri
suggest
measur
limit
transmiss
includ
patient
cohort
individu
respiratori
protect
natur
ventil
engin
control
neg
air
pressur
usual
avail
therefor
hcw
minim
time
spent
highrisk
area
poor
ventil
possibl
person
respiratori
protect
main
option
limit
exposur
treatment
latent
tuberculosi
strongli
recommend
us
hcw
latent
tuberculosi
detect
departur
often
best
delay
treatment
return
cdc
recommend
treatment
latent
tuberculosi
month
isoniazid
month
rifampin
latent
tuberculosi
diagnos
travel
highrisk
area
infect
mdr
xdr
tuberculosi
must
consid
exposur
mdr
xdr
tuberculosi
report
unlik
standard
treatment
indic
risk
signific
definit
exposur
occur
treatment
base
suspect
known
suscept
mdr
xdr
tuberculosi
exposur
consid
approach
often
taken
unit
state
base
expert
opinion
controversi
treatment
may
includ
month
either
ethambutol
pyrazinamid
levofloxacin
moxifloxacin
cdc
recommend
clinic
radiograph
followup
month
latent
tuberculosi
like
due
mdr
xdr
pathogen
regardless
whether
treatment
latent
tuberculosi
occur
tuberculosi
develop
rapid
identif
resist
critic
molecular
detect
drug
resist
avail
cdc
state
health
depart
consult
expert
strongli
advis
assist
avail
health
depart
cdc
region
train
medic
consult
center
medic
research
health
care
worker
travel
resourcelimit
set
conduct
patient
care
research
compos
understudi
travel
popul
natur
work
restrict
provis
suppli
potenti
limit
use
infectioncontrol
practic
put
uniqu
risk
acquir
specif
infect
review
provid
practic
guidanc
mitig
risk
potenti
occup
infecti
diseas
transmiss
set
aspir
rais
interest
studi
best
protect
individu
